Published : Oct-2019
No. of Pages : 151
1.1 List of Tables
1.2 List of Figures
2 Myasthenia Gravis: Executive Summary
2.1 MG Market Is Expected to Grow to $1.9B by 2028
2.2 Potential for Label Expansion for Immunosuppressants and Anti-Myasthenic Agents
2.3 Treatment-Related Costs Pose a Threat to Patient Compliance Rates
2.4 Steroid-Sparing Immunosuppressive Strategies Increasingly Favored by Clinicians and Patients
2.5 Complement Inhibitors Zilucoplan and Ravulizumab to Be Top-Selling Drugs in 2028
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.1 Forecast Assumptions and Methods
5.4.2 Forecast Assumptions - Diagnosed Prevalent Cases of MG
5.4.3 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of MG by Severity
5.5 Epidemiological Forecast for Myasthenia Gravis (2018-2028)
5.5.1 Diagnosed Prevalent Cases of MG
5.5.2 Age-Specific Diagnosed Prevalent Cases of Myasthenia Gravis
5.5.3 Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis
5.5.4 Diagnosed Prevalent Cases of Myasthenia Gravis by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
6.2 Reversible Acetylcholinesterase Inhibitors
6.3 Immunosuppressants
6.3.1 Azathioprine and Cyclosporine
6.3.2 Tacrolimus
6.4 Steroids
6.4.1 Glucocorticosteroid Receptor Agonists
6.4.2 Spironolactone
6.5 Monoclonal Antibodies
6.5.1 Rituxan/MabThera
6.5.2 Soliris
6.6 Non-pharmacotherapeutic Management of MG
6.6.1 Thymectomy
6.6.2 Intravenous Immunoglobulin and Plasmapheresis
6.7 Treatment Algorithms for Difficult-to-Treat Patients
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Greater Control over Treatment-Related Costs Blocking Access to Essential Medicines
7.3 Making Frequency of Administration Manageable for Intravenous Agents
7.4 Standardization of Treatment Guidelines for Different Disease Subtypes
7.5 Identifying Prognostic Biomarkers for MG
8 R&D Strategies
8.1 Overview
8.1.1 Repurposing Immunosuppressive Therapies for MG
8.1.2 Drugs Targeting Specific Components of the Immune System
8.1.3 Targeting Comorbidities of MG
8.2 Clinical Trials Design
8.2.1 Overview
8.2.2 Investigating the Feasibility of Non-invasive Routes of Administration in Treating MG
8.2.3 Generating Reliable Clinical Data for Off-Label Therapeutics
8.2.4 Assessing the Long-Term Safety of Biologics in Treating Refractory MG
9 Pipeline Assessment
9.1 Overview
9.2 Innovative Early Stage Approaches
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
11 Appendix
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer
List of Tables
Table 1: Myasthenia Gravis: Key Metrics in the 7MM
Table 2: MGFA Classification of MG
Table 3: Osserman Classification System
Table 4: Risk Factors and Comorbidities for MG
Table 5: Treatment Guidelines for MG in the 7MM
Table 6: Comparison of Therapeutic Classes in Development for MG, 2018-2028
Table 7: Innovative Early-Stage Approaches for MG, 2018
Table 8: Drugs in Development for MG, 2018
Table 9: Clinical Benchmark of Key Marketed and Pipeline Drugs - Synaptic Therapies Enhancing Neurotransmission of ACh in MG
Table 10: Clinical Benchmark of Key Marketed and Pipeline Drugs - Immunosuppressants in MG
Table 11: Commercial Benchmark of Key Marketed and Pipeline Drugs - Synaptic Therapies Enhancing Neurotransmission of ACh in MG.
Table 12: Commercial Benchmark of Key Marketed and Pipeline Drugs - Immunosuppressants in MG
Table 13: Key Events Impacting Sales for MG, 2018-2028
Table 14: MG Market - Global Drivers and Barriers, 2018-2028
Table 15: Key Historical and Projected Launch Dates for MG
Table 16: Key Historical and Projected Patent Expiry Dates for MG
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for MG in 2018 and 2028
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Mestinon
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Soliris
Figure 4: AChR and MuSK Blocked by Autoantibodies at the Neuromuscular Junction in MG
Figure 5: 7MM, Diagnosed Prevalence of MG, %, Both Sexes, All Ages, 2018
Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MG
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MG by Severity
Figure 8: 7MM, Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018
Figure 9: 7MM, Age-Specific Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018
Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of MG, N, All Ages, 2018
Figure 11: 7MM, Diagnosed Prevalent Cases of MG by Severity, N, Both Sexes, All Ages, 2018
Figure 12: Unmet Needs and Opportunities in MG
Figure 13: Overview of the Development Pipeline in MG
Figure 14: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for MG in the 7MM, 2018-2028
Figure 15: Competitive Assessment of Firdapse, the Pipeline Therapy Enhancing Neurotransmission of ACh, Benchmarked Against the SOC, Mestinon
Figure 16: Competitive Assessment of the Pipeline Immunosuppressants Benchmarked Against the SOC, Soliris
Figure 17: Global (7MM) Sales Forecast by Country for MG, 2018 and 2028
Figure 18: Global Sales Forecast by Class for MG, 2018 and 2028
Figure 19: Sales Forecast by Class for MG in the US, 2018 and 2028
Figure 20: Sales Forecast by Class for MG in the 5EU, 2018 and 2028
Figure 21: Sales Forecast by Class for MG in Japan, 2018 and 2028
